News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,367 Results
Type
Article (14257)
Company Profile (281)
Press Release (253829)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79575)
Career Advice (152)
Deals (13240)
Drug Delivery (35)
Drug Development (50506)
Employer Resources (31)
FDA (5730)
Job Trends (5139)
News (144538)
Policy (10043)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21686)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5758)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4566)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (58)
Brain cancer (20)
Breast cancer (155)
Cancer (1482)
Cardiovascular disease (117)
Career advice (133)
Career pathing (2)
CAR-T (118)
Cell therapy (332)
Cervical cancer (8)
Clinical research (41129)
Collaboration (542)
Compensation (260)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (165)
Cystic fibrosis (76)
Data (1529)
Denatured (11)
Depression (31)
Diabetes (139)
Diagnostics (1301)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29875)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48650)
Executive appointments (464)
FDA (6436)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (499)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (366)
Government (1082)
Grass and pollen (2)
Guidances (26)
Healthcare (6595)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1100)
Inflammatory bowel disease (114)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (67)
Interviews (17)
IPO (7279)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (209)
Leadership (3)
Legal (1388)
Liver cancer (33)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (54)
Medical device (2603)
Medtech (2604)
Mergers & acquisitions (6292)
Metabolic disorders (391)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1259)
NextGen: Class of 2025 (2019)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (78)
Peanut (35)
People (25661)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14527)
Phase II (19130)
Phase III (12097)
Pipeline (817)
Policy (45)
Postmarket research (852)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8654)
Reports (15)
Research institute (939)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (64)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1975)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (214)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (102)
Last 7 days (524)
Last 30 days (1523)
Last 365 days (19620)
2025 (6337)
2024 (20578)
2023 (22431)
2022 (26845)
2021 (27829)
2020 (23395)
2019 (16237)
2018 (11750)
2017 (13760)
2016 (11848)
2015 (14350)
2014 (10397)
2013 (7488)
2012 (7535)
2011 (7615)
2010 (7429)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17347)
Australia (2937)
California (3882)
Canada (1142)
China (361)
Colorado (149)
Connecticut (152)
Delaware (103)
Europe (37297)
Florida (467)
Georgia (117)
Idaho (16)
Illinois (233)
India (10)
Indiana (92)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (477)
Massachusetts (3091)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (972)
New Mexico (12)
New York (1053)
North Carolina (555)
North Dakota (5)
Northern California (1718)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (743)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1491)
Tennessee (25)
Texas (449)
United States (13325)
Utah (53)
Virginia (79)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,367 Results for "gv20 therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024
GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, today presented preclinical data on it GV20-0251 program during an oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
April 8, 2024
·
3 min read
Genetown
GV20 Therapeutics to Present at the Jefferies Healthcare Conference Private Biotech Day
GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it will present at the Jefferies Global Healthcare Conference Private Biotech Day, taking place June 4th, 2024, in New York.
May 22, 2024
·
1 min read
Genetown
GV20 Therapeutics Announces Oral Presentation on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024
GV20 Therapeutics announced that its abstract was selected for an oral presentation at the American Association of Cancer Research Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.
March 5, 2024
·
1 min read
Business
GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery
GV20 Therapeutics announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.
March 12, 2024
·
1 min read
Business
GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA® (pembrolizumab)
GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics, today announced that it has entered into a clinical collaboration and supply agreement with Merck (known as MSD outside the US and Canada).
April 18, 2024
·
2 min read
Genetown
GV20 Therapeutics to Present at the Needham 23rd Annual Virtual Healthcare Conference
GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it will present at the Needham 23rd Annual Virtual Healthcare Conference, taking place April 8-11, 2024.
April 2, 2024
·
1 min read
Genetown
GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target
GV20 Therapeutics today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.
April 24, 2024
·
2 min read
Business
GV20 Therapeutics Announces Appointment of Three Advisers
GV20 Therapeutics , a biopharmaceutical company using cutting-edge genomics and artificial intelligence approaches to discover next-generation cancer therapeutics, announced the appointment of three key advisers as it prepares to advance its first drug candidate into the clinic.
July 20, 2022
·
6 min read
Business
GV20 Therapeutics Builds Experienced Leadership Team with Appointments of Three Key Executives
Esteemed cancer researcher and co-founder of GV20 Shirley Liu appointed as Chief Executive Officer.
June 29, 2022
·
5 min read
GV20 Oncotherapy Completes Series B Financing to Advance Pipeline into the Clinic and Expand Immuno-Oncology Drug Discovery Platform
GV20 Oncotherapy today announced the completion of its Series B financing.
October 14, 2021
·
3 min read
1 of 26,837
Next
